New drug trial aims to shrink bulging eyes
NCT ID NCT07113262
Summary
This study is testing an investigational drug called IBI311 for people with inactive thyroid eye disease, a condition that can cause the eyes to bulge forward. About 111 participants will be randomly assigned to receive either the drug or a placebo to see if IBI311 can safely reduce eye bulging and improve symptoms like double vision. The study will last up to 64 weeks and is designed to see if the drug can control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Medical University
RECRUITINGShenyang, Liaoning, 110801, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.